Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

doi:10.1200/JCO.22.02186

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2023

Herbst Roy S, Wu Yi-Long, John Thomas, Grohe Christian, Majem Margarita, Wang Jie, Kato Terufumi, Goldman Jonathan W, Laktionov Konstantin, Kim Sang-We, Yu Chong-Jen, Vu Huu Vinh, Lu Shun, Lee Kye Young, Mukhametshina Guzel, Akewanlop Charuwan, de Marinis Filippo, Bonanno Laura, Domine Manuel, Shepherd Frances A, Urban Damien, Huang Xiangning, Bolanos Ana, Stachowiak Marta, Tsuboi Masahiro

Abstract excerpt

PURPOSE: The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemotherapy, Adjuvant

Share to Double-Blind Method

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 36720083
DOI: 10.1200/JCO.22.02186
PMCID: PMC10082285

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.PMID 36720083Read ↗

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.Semantic proximity Read ↗

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.Semantic proximity Read ↗

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.Semantic proximity Read ↗

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.Semantic proximity Read ↗

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.Semantic proximity Read ↗

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.Semantic proximity Read ↗

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.Semantic proximity Read ↗

Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.Semantic proximity Read ↗

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Semantic proximity Read ↗

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Semantic proximity Read ↗

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.